Vimarsana
Biggest News Aggregation in the World

Danielj Deangelo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Danielj Deangelo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Danielj Deangelo Today - Breaking & Trending Today

Uproleselan Plus SOC Targeted Regimens and Chemotherapy Under Investigation in AML - Vimarsana News

Uproleselan Plus SOC Targeted Regimens and Chemotherapy Under Investigation in AML

Published: July 28, 2023

Bhavana “Tina” Bhatnagar, DO, discusses the mechanism of action of uproleselan, the potential efficacy and safety benefits of adding this agent to standard therapeutic regimens in patients with AML, and the importance of considering MRD negativity as an end point in AML clinical trials.

Source: onclive.com
Related Topics:
United StatesBhavana Tina BhatnagarDanielj DeangeloOncology At West Virginia University Cancer InstituteDepartment Of Medicine At West Virginia UniversityUniversity Of CaliforniaWest Virginia UniversityMedical OncologyWest Virginia University Cancer InstitutePatients With Acute Myeloid LeukemiaUproleselan Plus MitoxantroneNd CytarabineUproleselan Plus Mec Or FludarabineNd IdarubicinUproleselan Plus Azacitidine And VenetoclaxPatients With Treatment Naïve AmlE Selectin Inhibition In The Aml Tumor MicroenvironmentAml Targets
Cogent Biosciences Announces Positive Updated Clinical Data - Vimarsana News

Cogent Biosciences Announces Positive Updated Clinical Data

Published: December 11, 2022

-   89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up -   Rapid and deep responses seen including...

Source: globenewswire.com
Related Topics:
United StatesAndrew RobbinsDanielj DeangeloCogent Research TeamBezuclastinib Clinical DevelopmentCogent Biosciences IncAmerican Society Of HematologyDivision Of LeukemiaDana Farber Cancer InstituteAmerican SocietyAnnual MeetingNew OrleansChief Executive OfficerOngoing PhaseBezuclastinib ClinicalGastrointestinal Stromal TumorsCogent BiosciencesPrivate Securities Litigation Reform ActQuarterly ReportNasdaq CogtCogent Biosciences